<DOC>
<DOCNO>EP-0636026</DOCNO> 
<TEXT>
<INVENTION-TITLE>
COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D25700	C07D26100	A61P2900	C07C25500	C07D26100	C07D20948	A61K31275	C07C27564	C07D26300	C07D30900	A61P2900	C07C27500	C07C4300	C07C27526	C07D27700	A61P3700	A61K3133	C07D23900	C07C25554	C07D20900	C07D27700	C07D23300	A61K3133	C07D25700	C07D30700	C07D21500	C07D29500	C07D29500	A61P3708	A61K31275	C07C25546	C07C4323	C07D26300	C07D23900	C07D21300	C07D30900	C07D30700	C07D21500	C07D23300	C07D21300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	A61P	C07C	C07D	C07D	A61K	C07C	C07D	C07D	A61P	C07C	C07C	C07C	C07D	A61P	A61K	C07D	C07C	C07D	C07D	C07D	A61K	C07D	C07D	C07D	C07D	C07D	A61P	A61K	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D257	C07D261	A61P29	C07C255	C07D261	C07D209	A61K31	C07C275	C07D263	C07D309	A61P29	C07C275	C07C43	C07C275	C07D277	A61P37	A61K31	C07D239	C07C255	C07D209	C07D277	C07D233	A61K31	C07D257	C07D307	C07D215	C07D295	C07D295	A61P37	A61K31	C07C255	C07C43	C07D263	C07D239	C07D213	C07D309	C07D307	C07D215	C07D233	C07D213	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel cyclohexane-ylidene derivatives of formula (I) are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; they are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV and are therefore useful in the treatment of disease states in need of mediation or inhibition thereof.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORP
</APPLICANT-NAME>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORPORATION
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CHRISTENSEN SIEGFRIED B IV
</INVENTOR-NAME>
<INVENTOR-NAME>
FORSTER CORNELIA JUTTA
</INVENTOR-NAME>
<INVENTOR-NAME>
CHRISTENSEN, SIEGFRIED, B., IV
</INVENTOR-NAME>
<INVENTOR-NAME>
FORSTER, CORNELIA, JUTTA
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to novel compounds, pharmaceutical compositions
containing these compounds, and their use in treating allergic and inflammatory diseases and
for inhibiting the production of Tumor Necrosis Factor (TNF).Bronchial asthma is a complex, multifactorial disease characterized by reversible
narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.Identification of novel therapeutic agents for asthma is made difficult by the fact that
multiple mediators are responsible for the development of the disease. Thus, it seems
unlikely that eliminating the effects of a single mediator will have a substantial effect on all
three components of chronic asthma. An alternative to the "mediator approach" is to regulate
the activity of the cells responsible for the pathophysiology of the disease.One such way is by elevating levels of cAMP (adenosine cyclic 3',5'-monophosphate).
Cyclic AMP has been shown to be a second messenger mediating the
biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs
Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29,
1973]. When the appropriate agonist binds to specific cell surface receptors, adenylate
cyclase is activated, which converts Mg+2-ATP to cAMP at an accelerated rate.Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the
pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would
produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of
mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of
basophil degranulation, and 5) inhibition of monocyte and macrophage activation. Hence,
compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in
suppressing the inappropriate activation of airway smooth muscle and a wide variety of
inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is
hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to
as cyclic nucleotide phosphodiesterases (PDEs).It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE)
isozyme, PDE IV, is responsible for cAMP breakdown in airway smooth muscle and
inflammatory cells. [Torphy, "Phosphodiesterase Isozymes: Potential Targets for Novel
Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd.,
1989]. Research indicates that
</DESCRIPTION>
<CLAIMS>
A compound of Formula (I):


wherein:

R
1
 is -(CR
4
R
5
)
n
C(O)O(CR
4
R
5
)
m
R
6
, -(CR
4
R
5
)
n
C(O)NR
4
(CR
4
R
5
)
m
R
6
,
-(CR
4
R
5
)
n
O(CR
4
R
5
)
m
R
6
, or -(CR
4
R
5
)
r
R
6
 wherein the alkyl moieties may be optionally
substituted with one or more halogens;
m is 0 to 2;
n is 1 to 4;
r is 1 to 6;
R
4
 and R
5
 are independently selected from hydrogen or a C
1-2
 alkyl;
R
6
 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC
1-3
 alkyl,
halo substituted aryloxyC
1-3
 alkyl, indanyl, indenyl, C
7-11
 polycycloalkyl,
tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl,

tetrahydrothiopyranyl, thiopyranyl, C
3-6
 cycloalkyl, or a C
4-6
 cycloalkyl containing one or
two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties may be optionally

substituted by 1 to 3 methyl groups or one ethyl group;

   provided that:

a) when R
6
 is hydroxyl, then m is 2; or
b) when R
6
 is hydroxyl, then r is 2 to 6; or
c) when R
6
 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,
or 2-tetrahydrothienyl, then m is 1 or 2; or
d) when R
6
 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,
or 2-tetrahydrothienyl, then r is 1 to 6;
e) when n is 1 and m is 0, then R
6
 is other than H in -(CR
4
R
5
)
n
O(CR
4
R
5
)
m
R
6
;
X is YR
2
, halogen, nitro, NR
4
R
5
, or formyl amine;
Y is O or S(O)
m'
;
m' is a number having a value of 0, 1, or 2;
X
2
 is O or NR
8
;
X
3
 is hydrogen or X;
R
2
 is independently selected from -CH
3
 or -CH
2
CH
3
 optionally substituted by 1 or
more halogens;
s is 0 to 4;
R
3
 is CN or C≡CR
8'
; 
Z is OR
14
, OR
15
, SR
14
, S(O)
m'
R
7
, S(O)
2
NR
10
R
14
, NR
10
R
14
, NR
14
C(O)R
9
,
NR
10
C(Y')R
14
, NR
10
C(O)OR
7
, NR
10
C(Y')NR
10
R
14
, NR
10
S(O)
2
NR
10
R
14
,
NR
10
C(NCN)NR
10
R
14
, NR
10
S(O)
2
R
7
, NR
10
C(CR
4
NO
2
)NR
10
R
14
,
NR
10
C(NCN)SR
9
, NR
10
C(CR
4
NO
2
)SR
9
, NR
10
C(NR
10
)NR
10
R
14
,
NR
10
C(O)C(O)NR
10
R
14
,or NR
10
C(O)C(O)OR
14
;
Y' is O or S;
R
7
 is -(CR
4
R
5
)
q
R
12
 or C
1-6
 alkyl wherein the R
12
 or C
1-6
 alkyl group is
optionally substituted one or more times by C
1-2
 alkyl optionally substituted by one to
three fluorines, -F, -Br, -Cl, -NO
2
, -NR
10
R
11
, -C(O)R
8
, -C(O)OR
8
, -OR
8
, -CN,
-C(O)NR
10
R
11
, -OC(O)NR
10
R
11
, -OC(O)R
8
, -NR
10
C(O)NR
10
R
11
, -NR
10
C(O)R
11
,
-NR
10
C(O)OR
9
, -NR
10
C(O)R
13
, -C(NR
10
)NR
10
R
11
, -C(NCN)NR
10
R
11
,
-C(NCN)SR
9
, -NR
10
C(NCN)SR
9
, -NR
10
C(NCN)NR
10
R
11
, -NR
10
S(O)
2
R
9
, -S(O)
m'
R
9
,
-NR
10
C(O)C(O)NR
10
R
11
, -NR
10
C(O)C(O)R
10
, thiazolyl, imidazolyl, oxazolyl,
pyrazolyl, triazolyl, or tetrazolyl;
q is 0, 1, or 2;
R
12
 is C
3-7
 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-
imidazolyl), thiazolyl, triazolyl, pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2-or

3-thienyl), (4- or 5-thiazolyl), quinolinyl, naphthyl, or phenyl;
R
8
 is independently selected from hydrogen or R
9
;
R
8
, is R
8
 or fluorine;
R
9
 is C
1-4
 alkyl optionally substituted by one to three fluorines;
R
10
 is OR
8
 or R
11
;
R
11
 is hydrogen, or C
1-4
 alkyl optionally substituted by one to three fluorines; or
when R
10
 and R
11
 are as NR
10
R
11
 they may together with the nitrogen form a 5 to 7
membered ring optionally containing at least one additional heteroatom selected from O, N,

or S;
R
13
 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl,
imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these

heterocyclic rings is connected through a carbon atom and each may be unsubstituted or
substituted by one or two C
1-2
 alkyl groups;
R
14
 is hydrogen or R
7
; or when R
10
 and R
14
 are as NR
10
R
14
 they may together
with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional

heteroatoms selected from O, N, or S;
R
15
 is C(O)R
14
, C(O)NR
4
R
14
, S(O)
2
R
7
, or S(O)
2
NR
4
R
14
;

   provided that:

f) when Z is OH, X is YR
2
, Y is oxygen, X
2
 is oxygen, X
3
 is hydrogen, s is 0, R
2

is CH
3
 in YR
2
, and R
1
 is CH
3
, then R
3
 is other than CN;
g) when R
12
 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N-piperazinyl,
N-piperidinyl, or N-morpholinyl, then q is not 1;
; or the pharmaceutically acceptable salts thereof.
A compound of Formula (Ia) and (Ib)


wherein:

R
1
 is -CH
2
-cyclopropyl, -CH
2
-C
5-6
 cycloalkyl, -C
4-6
 cycloalkyl, C
7-11

polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C
1-2
 alkyl
optionally substituted by 1 or more fluorines, -(CH
2
)
1-3
C(O)O(CH
2
)
0-2
CH
3
,
-(CH
2
)
1-3
O(CH
2
)
0-2
CH
3
, and -(CH
2
)
2-4
OH;
X is YR
2
, halogen, nitro, NR
4
R
5
, or formyl amine;
Y is O or S(O)
m
';
m' is 0, 1, or 2;
R
2
 is -CH
3
 or -CH
2
CH
3
 optionally substituted by 1 or more halogens;
R
3
 is CN or C≡CR
8
;
Z is OR
14
, OR
15
, SR
14
, S(O)
m
'R
7
, S(O)
2
NR
10
R
14
, NR
10
R
14
, NR
14
C(O)R
9
,
NR
10
C(O)R
14
, NR
10
C(O)OR
7
, NR
10
C(O)NR
10
R
14
, NR
10
S(O)
2
NR
10
R
14
,
NR
10
C(NCN)NR
10
R
14
, NR
10
S(O)
2
R
7
, NR
10
C(CR
4
NO
2
)NR
10
R
14
,
NR
10
C(NCN)SR
9
, NR
10
C(CR
4
NO
2
)SR
9
, NR
10
C(NR
10
)NR
10
R
14
,
NR
10
C(O)C(O)NR
10
R
14
, or NR
10
C(O)C(O)OR
14
;
R
7
 is -(CR
4
R
5
)
q
R
12
 or C
1-6
 alkyl wherein the R
12
 or C
1-6
 alkyl group is
optionally substituted one or more times by C
1-2
 alkyl optionally substituted by one to
three fluorines, -F, -Br, -Cl, -NO
2
, -NR
10
R
11
, -C(O)R
8
, -C(O)OR
8
, -OR
8
, -CN,
-C(O)NR
10
R
11
, -OC(O)NR
10
R
11
, -OC(O)R
8
, -NR
10
C(O)NR
10
R
11
, -NR
10
C(O)R
11
,
-NR
10
C(O)OR
9
, -NR
10
C(O)R
13
, -C(NR
10
)NR
10
R
11
, -C(NCN)NR
10
R
11
,
-C(NCN)SR
9
, -NR
10
C(NCN)SR
9
, -NR
10
C(NCN)NR
10
R
11
, -NR
10
S(O)
2
R
9
, -S(O)
m
'R
9
,
-NR
10
C(O)C(O)NR
10
R
11
, -NR
10
C(O)C(O)R
10
, thiazolyl, imidazolyl, oxazolyl,
pyrazolyl, triazolyl, or tetrazolyl;
q is 0, 1, or 2;
R
12
 is C
3-7
 cycloalkyl, (2-, 3- or 4-pyridyl), (1- or 2-imidazolyl), piperazinyl,
morpholinyl, (2- or 3-thienyl), (4- or 5-thiazolyl), or phenyl;
R
8
 is independently selected from hydrogen or R
9
;
R
9
 is C
1-4
 alkyl optionally substituted by one to three fluorines;
R
10
 is OR
8
 or R
11
;
R
11
 is hydrogen or C
1-4
 alkyl optionally substituted by one to three fluorines; or
when R
10
 and R
11
 are as NR
10
R
11
 they may together with the nitrogen form a 5 to 7 
membered ring optionally containing at least one additional heteroatom selected from O, N,

or S;
R
13
 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl,
imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these

heterocyclic rings is connected through a carbon atom and each may be unsubstituted or
substituted by one or two C
1-2
 alkyl groups;
R
14
 is hydrogen or R
7
; or when R
10
 and R
14
 are as NR
10
R
14
 they may together
with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional

heteroatoms selected from O, N, or S;
R
15
 is C(O)R
14
, C(O)NR
4
R
14
, S(O)
2
R
7
, or S(O)
2
NR
4
R
14
;

   provided that:

a) when Z is OH, X is YR
2
, Y is oxygen, X
2
 is oxygen, X
3
 is hydrogen, s is 0, R
2

is CH
3
 in YR
2
, and R
1
 is CH
3
, then R
3
 is other than CN;
b) when R
12
 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N-piperazinyl,
N-piperidinyl, or N-morpholinyl, then q is not 1;

   or the pharmaceutically acceptable salts thereof.
A compound according to claim 2, wherein R
1
 is -CH
2
-cyclopropyl, -CH
2
-C
5-6

cycloalkyl, -C
4-6
 cycloalkyl, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -C
1-2

alkyl optionally substituted by 1 or more fluorines, and -(CH
2
)
2-4
 OH; R
2
 is methyl or
fluoro-substituted alkyl, R
3
 is CN or C≡CR
8
; and X is YR
2
.
A compound according to any one of claims 2 or 3, wherein R
1
 is
-CH
2
-cyclopropyl, cyclopentyl, methyl or CF
2
H; R
3
 is CN or C≡CH; X is YR
2
; Y is
oxygen; X
2
 is oxygen; X
3
 is hydrogen; and R
2
 is CF
2
H or methyl.
A compound of claim 1 which is:

cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-ol];
trans
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-ol];
cis
-[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)cyclohexan-1-ol];
cis-
[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-cyclohexan- 1-ol];
trans
-[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)cyclohexan-1-ol;
cis
-[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol];
trans-
 [4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol;
cis-
[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-ethynylcyclohexan- 1-ol];
trans-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)- 1-formyloxycyclohexane];
trans
-4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-cyclohexan-1-ol;
trans-
[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-formyloxycyclohexane]; 
cis-
 [4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-methylcyclohexan-1-ol],
trans
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-methylcyclohexan-1-ol];
cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexyl-1-amine];
trans-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexyl-1-amine];
cis
- [4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl-1-amine];
cis
-[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)cyclohexyl-1-amine];
trans-
[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)cyclohexyl- 1-amine];
cis-
[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl-1-(N,N-dimethyl)amine];
cis
-[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)cyclohexyl-1-N,N-dimethyl)amine];
cis
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl-1-(N-methyl)amine];
trans
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl-1-(N-methyl)amine];
trans
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-phthalimidocyclohexane];
trans-
[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-phthalimidocyclohexane];
trans
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl-1-amine];
trans-
[1-N-(2-hydrazinocarbonylbenzamido)-4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexane];
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)- 1-ureidocyclohexane];
cis
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-ureidocyclohexane];
trans-
[4-(3,4-bisdifluoromethoxyphenyl)-4-cyano-1-ureidocyclohexane];
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
trans
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
cis
-[4-cyano-4-(3-{ 4-fluorobenzyl }-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
trans
-[4-cyano-4-(3-{4-fluorobenzyl}-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
cis-
[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
trans-
[4-cyano-4-(3-cyclopropylmethoxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
cis
-[1-acetamido-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane];
trans-
[1 -acetamido-4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexane];
methyl N-{
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-cyclohexyl}-1-oxamate];
methyl N-{
trans
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl}-1-oxamate]; 
N-{
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexyl}-1-oxamide];

N-{
trans
-[4-(3,4-bisdifluoromethoxyphenyl)-4-cyanocyclohexyl}-1-oxamide];
N-{
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexyl}-1-oxamic
acid]
;
cis
-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-methoxycyclohexane];
trans-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-methoxycyclohexane]

cis-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyamino)-cyclohexane];
trans-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyamino)-cyclohexane]
;
cis-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];

and
trans-
[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-(N-hydroxyureido)-cyclohexane];
cis
-[4-cyano-4-(3-{ 4-fluorobenzyl}-4-methoxyphenyl)-1-(N-hydroxyamino)-cyclohexane];
trans
-[4-cyano-4-(3-{ 4-fluorobenzyl}-4-methoxyphenyl)-1-(N-hydroxyamino)-cyclohexane].
A pharmaceutical composition comprising a compound of Formula (I) according to
claim 1 or a compound of Formula (Ia) or a compound of Formula (Ib) according to claim

2, and a pharmaceutically acceptable excipient.
A compound of Formula (I) according to claim 1 or a compound of Formula (Ia) or
a compound of Formula (Ib) according to claim 2, for use in inhibiting TNF production.
A compound of Formula (I) according to claim 1 or a compound of Formula (Ia) or
a compound of Formula (Ib) according to claim 2, for use in the treatment of allergic and

inflammatory disease.
</CLAIMS>
</TEXT>
</DOC>
